Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma
Autore:
Krishna, MT; Chauhan, A; Little, L; Sampson, K; Hawksworth, R; Mant, T; Djukanovic, R; Lee, T; Holgate, S;
Indirizzi:
Univ Southampton, Southampton Gen Hosp, RCMB Div, Southampton SO16 6YD, Hants, England Univ Southampton Southampton Hants England SO16 6YD 6 6YD, Hants, England Guys Drug Res Unit, London, England Guys Drug Res Unit London EnglandGuys Drug Res Unit, London, England Guys Hosp, GKT Sch Med, Dept Resp Med & Allergy, London, England Guys Hosp London England Med, Dept Resp Med & Allergy, London, England
Titolo Testata:
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
fascicolo: 6, volume: 107, anno: 2001,
pagine: 1039 - 1045
SICI:
0091-6749(200106)107:6<1039:IOMCTB>2.0.ZU;2-3
Fonte:
ISI
Lingua:
ENG
Soggetto:
INCREASED BRONCHIAL RESPONSIVENESS; ATOPIC SUBJECTS; HISTAMINE; HYPERRESPONSIVENESS; RELEASE; BRONCHOCONSTRICTION; EOSINOPHIL; ACTIVATION; RESPONSES; INFLAMMATION;
Keywords:
APC 366; late asthmatic response; tryptase; asthma; mast cell; airway inflammation; bronchial hyperresponsiveness; early asthmatic response;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
38
Recensione:
Indirizzi per estratti:
Indirizzo: Krishna, MT Univ Southampton, Southampton Gen Hosp, RCMB Div, Mail Point 810,Level D,Ctr Block,Tremona Rd, Southampton SO16 6YD, Hants, England Univ Southampton Mail Point 810,Level D,Ctr Block,Tremona Rd Southampton Hants England SO16 6YD
Citazione:
M.T. Krishna et al., "Inhibition of mast cell tryptase by inhaled APC 366 attenuates allergen-induced late-phase airway obstruction in asthma", J ALLERG CL, 107(6), 2001, pp. 1039-1045

Abstract

Background: APC 366, a selective inhibitor of mast cell tryptase, has beenshown to inhibit antigen-induced early asthmatic response (EAR), late asthmatic response (LAR), and bronchial hyperresponsiveness (BHR) in a sheep model of allergic asthma,Objective: The purpose of this study was to investigate the effects of APC366 on antigen-induced EAR, LAR, and BHR in mild atopic asthmatics not on any anti-inflammatory therapyMethods: Sixteen mild atopic asthmatics, each with a demonstrable antigen-induced EAR, LAR, and BHR to histamine, were recruited into this randomized, double-blinded, crossover study. APC 366 (5 mg)/placebo was administered by aerosol inhalation 3 times per day on treatment days 1 through 4, Allergen challenge was carried out on day 4. Histamine challenge was performed the following morning, 1 hour after Final dosing. Results: Subjects were shown to have a significantly smaller overall mean area under the curve for the LAR (P = .012) and mean maximum fall in FEV1 for the LAR (P = .007) after pretreatment with APC 366 in comparison with placebo. No significant effects on BHR were demonstrable. Although the EAR was reduced by 18% after treatment with APC 366 in comparison with placebo, this was not statistically significant. Conclusion: Short-term repeated administration of APC 366 significantly reduced the magnitude of antigen-induced LAR in atopic asthmatics, which supports the role of mast cell tryptase in the pathophysiology of the LAR.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/02/20 alle ore 21:22:26